Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.760
-0.010 (-0.56%)
Apr 15, 2025, 4:00 PM EDT - Market closed
Inovio Pharmaceuticals Revenue
In the year 2024, Inovio Pharmaceuticals had annual revenue of $217.76K, down -73.83%. Inovio Pharmaceuticals had revenue of $116.99K in the quarter ending December 31, 2024, with 13.97% growth.
Revenue (ttm)
$217.76K
Revenue Growth
-73.83%
P/S Ratio
220.78
Revenue / Employee
$1,625
Employees
134
Market Cap
64.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 217.76K | -614.25K | -73.83% |
| Dec 31, 2023 | 832.01K | -9.43M | -91.89% |
| Dec 31, 2022 | 10.26M | 8.49M | 478.23% |
| Dec 31, 2021 | 1.77M | -5.64M | -76.05% |
| Dec 31, 2020 | 7.41M | 3.30M | 80.24% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
INO News
- 6 days ago - INOVIO to Present at Upcoming Scientific Conferences - PRNewsWire
- 4 weeks ago - Inovio Pharmaceuticals, Inc. (INO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights - PRNewsWire
- 4 weeks ago - INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19 - PRNewsWire
- 4 weeks ago - INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025 - PRNewsWire
- 2 months ago - Inovio Pharmaceuticals Inc (INO) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Transcript) - Seeking Alpha
- 2 months ago - Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications - PRNewsWire
- 2 months ago - Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference - PRNewsWire